Is BioCardia, Inc. (BCDAW) a Buy, Sell, or Hold?
NASDAQ : BCDAW
BioCardia, Inc.
$0.0061 USD
$0.0 (-3.17%)
- Volume
- 18.71K
- Average Volume
- 12.35K
- Market Capitalization
- $10.12K
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.01
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.41
Company Overview
NASDAQ
Peter A. Altman
Biotechnology
Healthcare
BCDAW
16
US
USD
Liquidity Metrics
-0.39
0.41
0.41
0.34
0.00
Sales & Valuation
-$
0.00
-0.06
0.00
-0.69
Profitability
-$1.23
-$8.23M
0.00%
0.00%
-5456.14%
-454.15%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-147.47
3/9
-$1.64M
$1.71M
$2.78M
-$3.53M
Key Metrics (TTM)
-$528.88K
0.00
0.15
0.41
-5456.14%
313.61%
-11788.21%
-74011.47%
0 days
Company Executives
| Name | Title |
|---|---|
| David McClung | Chief Financial Officer |
| Peter A. Altman | Chief Executive Officer, President & Director |
| Edward Gillis | Senior Vice President of Devices |
Poll Results
No votes yet today — be the first to share your view!
About BioCardia, Inc. (NASDAQ:BCDAW) Stock
BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardial ischemia. In parallel, the company is advancing allogeneic cell therapies for various heart and lung diseases, including an investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells, which is presently in Phase I/II trials for ischemic heart failure. Beyond its therapeutic pipeline, BioCardia provides the Helix biotherapeutic delivery system, engineered to precisely inject treatments into the heart muscle via an int ... ernal helical needle, alongside Morph deflectable guides and sheaths. The company's operations are headquartered in Sunnyvale, California.
Frequently Asked Questions
-
What is the current BioCardia, Inc. (BCDAW) stock price?
-
BioCardia, Inc.(NASDAQ:BCDAW) stock price is $0.0061 in the last trading session. During the trading session, BCDAW stock reached the peak price of $0.0063 while $0.0061 was the lowest point it dropped to. The percentage change in BCDAW stock occurred in the recent session was --3.17% while the dollar amount for the price change in BCDAW stock was -$0.0.
-
BCDAW's industry and sector of operation?
-
The NASDAQ listed BCDAW is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCDAW?
-
David McClung | Chief Financial Officer
Peter A. Altman | Chief Executive Officer, President & Director
Edward Gillis | Senior Vice President of Devices
|
| -
How many employees does BCDAW have?
-
Number of BCDAW employees currently stands at 16. BCDAW operates from 320 Soquel Way, Sunnyvale, CA 94085, US.
-
Link for BCDAW official website?
-
Official Website of BCDAW is: https://www.biocardia.com
-
How do I contact BCDAW?
-
BCDAW could be contacted at phone #650 226 0120 and can also be accessed through its website. BCDAW operates from 320 Soquel Way, Sunnyvale, CA 94085, US.
-
How many shares of BCDAW are traded daily?
-
The average number of BCDAW shares traded daily for last 3 months was 12.35K.
-
What is the market cap of BCDAW currently?
-
The market value of BCDAW currently stands at $10.12K with its latest stock price at $0.0061